HCW Biologics Inc is trading 8% down at $1.50 in pre-market, extending recent pressure on small-cap biotech names following stronger-than-expected U.S. jobs data.
- The move reflects a broader risk-off sentiment in growth assets as investors weigh the potential for further interest rate hikes.
- There are no company-specific catalysts or fundamental developments reported this morning; the decline appears driven by macro-driven volatility and sector-wide weakness.